وڌيڪ ڄاڻ ― سنڌي

Squamous cell carcinoma (SCC) آمريڪا ۾ basal cell carcinoma کان پوءِ ٻيو سڀ کان وڌيڪ عام چمڙي جو ڪينسر آهي. اهو عام طور تي actinic keratosis جي اڳڪٿي واري زخم سان شروع ٿئي ٿو، ۽ جسم جي ٻين حصن تائين پکڙجي سگهي ٿو. ان جو بنيادي سبب سج مان نڪرندڙ الٽراوائلٽ (UV) شعاعن جي نمائش آهي، جيڪا وقت سان گڏ وڌندي رهي ٿي. علاج ۾ عام طور تي جراحي هٽائڻ شامل آهي، خاص طور تي سر ۽ ڳچيءَ تي SCC لاءِ. ريڊيئيشن علاج هڪ اختيار آهي پراڻي مريضن يا انهن لاءِ جيڪي سرجري نٿا ڪري سگهن. Immunosuppression SCC جو خطرو وڌائي ٿو. جيتوڻيڪ نادر، SCC پکڙجي سگهي ٿو، خاص طور تي انهن مريضن ۾ جن جو مدافعتي نظام ڪمزور آهي. باقاعده چيڪ اپ ۽ سج جي حفاظت انهن لاءِ اهم آهن جيڪي SCC سان متاثر آهن.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.

Cutaneous squamous cell carcinoma (CSCC) ماڻهن ۾ ٻيو سڀ کان عام ڪينسر آهي، ۽ ان جو تعداد وڌي رهيو آهي. جيتوڻيڪ CSCC عام طور تي غير معمولي ڪلينڪل رويي ڏيکاري ٿو، اهو مقامي طور تي ۽ جسم جي ٻين حصن تائين پکڙجي سگهي ٿو. سائنسدانن CSCC جي ترقي ۾ شامل مخصوص رستن جي نشاندهي ڪئي آهي، جيڪا نئين علاج جي ترقي کي اڳواڻي ڏئي ٿي. ميوٽيشنز جو وڏو تعداد ۽ اموناسپريس ٿيل مريضن ۾ وڌندڙ خطرو immunotherapy جي ترقي کي تيز ڪيو آهي. هي جائزو CSCC جي جينيتي جڙ ۽ جديد علاجن کي خاص ماليڪيولز ۽ مدافعتي نظام کي نشانو بڻائيندو آهي.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors